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http://www.biomedcentral.com/1471-2369/14/146RESEARCH ARTICLE Open AccessDiastolic dysfunction is associated with an
increased risk of contrast-induced nephropathy:
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Background: Contrast-induced nephropathy (CIN) is the third leading cause of hospital-acquired acute kidney
injury, and it is associated with poor long-term clinical outcomes. Although systolic heart failure is a well-known risk
factor for CIN, no studies have yet evaluated the association between diastolic dysfunction and CIN.
Methods: We conducted a retrospective study of 735 patients who underwent percutaneous transluminal coronary
angioplasty (PTCA) and had an echocardiography performed within one month of the procedure at our institute,
between January 2009 and December 2010. CIN was defined as an increase of ≥ 0.5 mg/dL or ≥ 25% in serum
creatinine level during the 72 hours following PTCA.
Results: CIN occurred in 64 patients (8.7%). Patients with CIN were older, had more comorbidities, and had an
intra-aortic balloon pump (IABP) placed more frequently during PTCA than patients without CIN. They showed
greater high-sensitivity C-reactive protein (hs-CRP) levels and lower estimated glomerular filtration rates (eGFR).
Echocardiographic findings revealed lower ejection fraction and higher left atrial volume index and E/E’ in the CIN
group compared with non-CIN group. When patients were classified into 3 groups according to the E/E’ values of 8
and 15, CIN occurred in 42 (21.6%) patients in the highest tertile compared with 20 (4.0%) in the middle and 2
(4.3%) in the lowest tertile (p < 0.001). In multivariate logistic regression analysis, E/E’ > 15 was identified as an
independent risk factor for the development of CIN after adjustment for age, diabetes, dose of contrast media, IABP
use, eGFR, hs-CRP, and echocardiographic parameters [odds ratio (OR) 2.579, 95% confidence interval (CI)
1.082-5.964, p = 0.035]. In addition, the area under the receiver operating characteristic curve of E/E’ was 0.751
(95% CI 0.684-0.819, p < 0.001), which was comparable to that of ejection fraction and left atrial volume index
(0.739 and 0.656, respectively, p < 0.001).
Conclusions: This study demonstrated that, among echocardiographic variables, E/E' was an independent predictor
of CIN. This in turn suggests that diastolic dysfunction may be a useful parameter in CIN risk stratification.
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Contrast-induced nephropathy (CIN) is one of the prin-
cipal complications which develop after procedures
using contrast media (CM). Although there are some
differences between institutions, the most commonly
used definition of CIN in clinical trials is a rise in serum
creatinine of > 0.5 mg/dL or > 25% from the baseline
value within 72 hours after exposure to the CM. The in-
cidence of CIN is reported to be about 2% in the general
population, 7-15% in patients undergoing percutaneous
coronary intervention, whereas it increases up to 50% in
high-risk patients with diabetes (DM) and renal failure
[1,2]. Recently, risk stratification and application of pre-
ventive methods against CIN further reduced the inci-
dence of CIN. However, CIN is still an important
problem in that dependence for medical procedures
using CM is steadily increasing and that it is closely re-
lated with poor long-term clinical outcomes: longer hos-
pital stay, and increased mortality and post-procedural
cardiovascular complications [3,4].
Accordingly, many investigators have tried to reveal
the pathogenesis of CIN. Delineated mechanisms include
intra-renal vasoconstriction, reduced renal blood flow,
medullary hypoxia, oxidative stress, inflammation, endo-
thelial dysfunction, and direct tubular-epithelial cell
injury by CM [5]. At the same time, risk factors potenti-
ating the processes explained above were proved out:
renal failure, old age, DM, congestive heart failure
(CHF), hypotensive event, use of intra-aortic balloon
pump (IABP), and ionic/ high-osmolar CM [6].
CHF, especially in advanced stages of New York Heart
Association (NYHA) class 3–4 contributes to the devel-
opment of CIN primarily by decreasing renal perfusion.
It is related with systolic dysfunction and low stroke vol-
ume [7]. In fact, some researches specifically pointed
ejection fraction (EF) < 30-40% out as an independent
predictor of CIN [8]. However, CHF per se and just a
past history of heart failure increased the incidence of
CIN, irrespective of EF [9,10]. Nevertheless, no studies
have yet evaluated the association between diastolic dys-
function and CIN.
The golden standard estimating diastolic function of
the heart is to measure left ventricular end-diastolic
pressure (LVEDP) with catheterization. However, it is in-
vasive and not a routine practice. On the other hand, E/
E’ can be assessed non-invasively with echocardiography,
and is known to be less influenced by heart rate, atrial
activity, or ejection fraction [11]. In addition, E/E’ levels
were well correlated with LVEDP, when patients were
categorized into 3 groups based on the E/E’ values of 8
and 15 [12]. E/E’ > 11 also predicted LVEDP > 15 mmHg
with a sensitivity of 75% and a specificity of 93% [13].
Among various doppler estimates of diastolic function
such as E, E/A, decrease in E/A with the valsalvamaneuver, deceleration time (DT), and pulmonary ven-
ous atrial reversal duration, E/E’ showed the highest pre-
dictive power for LVEDP [12].
So, we aimed to investigate whether E/E’ is an inde-
pendent risk factor predicting the development of CIN.
Effects of E/E’ and CIN on patient mortality were also
evaluated.Methods
Ethics statement
This study was carried out in accordance with the Dec-
laration of Helsinki and approved by the Institutional
Review Board (IRB) of Yonsei University Health System
Clinical Trial Center. Written consents were not re-
quired because this was a retrospective medical record-
based study and personally identifiable information was
anonymized.Patients
This retrospective study included 735 patients who
underwent percutaneous transluminal coronary angio-
plasty (PTCA) at Severance Hospital in Seoul, Korea
from January 2009 to December 2010. PTCA was
conducted in 6837 patients for the following reasons: 1)
regular follow-up for known coronary artery occlusive
disease (CAOD), 2) suspicion for CAOD based on clin-
ical symptoms or study results (treadmill test, techne-
tium sestamibi scan, or cardiac CT or MRI), or 3) to
evaluate whether idiopathic CHF was due to ischemia.
Among these, 3302 subjects who had undergone echo-
cardiography within 1 month of PTCA were included.
Exposure to other CM within 7 days of PTCA (n =
1576), an absence of data on serum creatinine during
the 72 hours following the procedure (n = 503), end-
stage renal disease (n = 408), underlying malignancy
(n = 43), acute infection (n = 28), or age less than 18
years (n = 9) resulted in the exclusion of an additional
2567 patients.
All patients were hydrated with 0.9% saline at a rate of
1.0 mL/kg/hour for 12 hours pre- and post-exposure to
the CM, according to the guidelines of our clinic. In case
of an emergency procedure, hydration was initiated im-
mediately prior to the start of angiography and contin-
ued for 24 hours after PTCA. Infusion rate was reduced
to 0.5 mL/kg/hour when pulmonary edema was noted or
ejection fraction was less than 30%.
Non-ionic, dimeric, and iso-osmolar contrast agent
(iodixanol: Visipaque, GE Healthcare, Amersham, United
Kingdom) was used for PTCA. A hypotensive event was
defined as systolic blood pressure < 80 mmHg for at
least 1 hour requiring inotropic therapy or IABP inser-
tion within 24 hours of procedure, as described by
Mehran et al. [14].
 
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Demographic and clinical data at the time of the PTCA
were collected through medical chart review. Labo-
ratory findings which were reported 24 hours prior to
the PTCA and measured in overnight fasting status,
were set as baseline values. CIN was defined as an
increase of ≥ 0.5 mg/dL or ≥ 25% in serum creatinine
level during the 72 hours following PTCA, that could
not be better explained by alternative etiologies. We
also used a second definition of CIN according to the
Acute Kidney Injury Network (AKIN) criteria: a rise
in serum creatinine ≥ 0.3 mg/dL within 48 hours of
procedure [3,15]. Oliguria was not considered because all
patients were hydrated and some of them used diuretics.
Hemoglobin, albumin, blood urea nitrogen, creatin-
ine, serum cholesterol, triglycerides, and glucose levels
were measured by an Advia 2120 Hematology Analyzer
(Siemens Health-care Diagnostics, Deerfield, Illinois).
High-sensitivity C-reactive protein (hs-CRP) levels
were measured with a BN II analyzer (Dade Behring,
Newark, DE, USA) using the latex-enhanced immuno-
nephelometric method. The estimated glomerular fil-
tration rate (eGFR) was calculated using the Modification
of Diet in Renal Disease (MDRD) equation [16].
Cardiac status and echocardiographic parameters
Records of PTCA were reviewed for the urgency of
the procedure, amount of CM used, interventional
strategy, and the number of coronary arteries involved.
We also investigated whether any patients had under-
gone coronary artery bypass graft surgery previously.
Echocardiography was performed with a SONOS
7500 (Philips Ultrasound, Bothell, WA, USA) ac-
cording to the recommendations of the American
Society of Echocardiography (ASE). Inter-ventricular
septal thickness (IVSs, IVSd), posterior wall thickness
(PWTs, PWTd), left ventricular end-diastolic di-
mension (LVDd), and left ventricular end-systolic di-
mension (LVDs) were measured in 2-dimensional M-
mode. Pulsed wave doppler was applied to check vel-
ocities in the 4-chamber apical view. Volume sam-
pling was positioned at the tip of the mitral valve to
measure early LV filling velocity (E) and left atrial
contraction velocity (A). Tissue doppler was then
conducted with the volume sampling repositioning at
the septal annulus of the mitral valve to measure early
(E’) and late (A’) diastolic mitral annular velocities.
LV systolic function was defined by EF. The EF was
calculated by the modified Simpson’s method, sub-
tracting LVDs from LVDd. LV mass (LVM) was esti-
mated using the Devereux modified ASE cube
formula [17], and the LV mass index (LVMI) was cal-
culated by dividing LVM by body surface area.LVM ¼ 0:8  1:04  IVSd þ LVDd
þ PWTd3  LVDd3þ 0:6 ðgmÞ
E/E’ and E/A were calculated to represent diastolic
function. DT, the time between peak E wave and the
upper deceleration slope extrapolated to zero line, was
also determined. In 23 patients exhibiting atrial fibrilla-
tion (n = 21, 3.1% in non-CIN group and n = 2, 3.1%
in CIN group), average measurements from 10 cardiac
cycles were used [11].
Left atrial volume index (LAVI), a marker of volume
status, was estimated with the biplane Simpson’s method
using the diameters of the LA, which were measured 3
times at the parasternal long axis view (anterior-poster-
ior, superior-inferior) and the 4 chamber view (medio-
lateral).
Inter-reader reliability, intra-reader reliability, and
reader drift analyses were performed on a random sam-
ple of 3% of the entire cohort. The intra-class correlation
coefficients for the echocardiographic measures were
0.845 for EF, 0.765 for LVMI, and 0.753 for LAVI.
Statistical analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences (SPSS) for Windows,
version 18.0 (Chicago, IL, USA). Data are expressed as a
mean ± standard deviation for continuous variables, and
as a number and percentage for categorical variables.
Normality of distribution was examined by the Shapiro-
Wilk test.
We compared the demographic, laboratory, and echo-
cardiographic parameters of patients with CIN with
those of patients without CIN using the Student’s t-test,
Mann–Whitney U test, or chi-square test. Either
ANOVA or the Kruskal-Wallis test was performed to
compare the 3 groups, which were classified according
to the E/E’ values of 8 and 15. Univariate and multivari-
ate binary logistic regression analyses were conducted to
identify risk factors predicting the development of CIN.
We also performed receiver operating characteristic
(ROC) analysis to confirm the predictive accuracy of
echocardiographic parameters for CIN. All-cause mor-
tality was compared between patients using 4 groupings
that were based on the presence or absence of diastolic
dysfunction (E/E’ > 15) and CIN, by Kaplan-Meier and
log-rank test. A p-value of less than 0.05 was considered
statistically significant.
Results
Baseline characteristics between patients with CIN and
those without CIN
Baseline characteristics of the study subjects are detailed
in Table 1. The mean age was 64.8 ± 10.6 years and 69.9%
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20.5 mL/min/1.73m2 and 13.3 ± 5.3, respectively. A total
of 64 patients (8.7%) developed CIN.
When patients were dichotomized into CIN and non-
CIN groups, the CIN group was older and had lowerTable 1 Baseline characteristics of study subjects
Variables All (n = 735
Age (years) 64.8 ± 10.6
Sex (male) 514 (69.9%
BMI (kg/m2) 24.5 ± 3.3
Systolic BP (mmHg) 119.6 ± 15.1
Diastolic BP (mmHg) 71.9 ± 9.9
Hypertension 475 (64.6%
Diabetes mellitus 250 (34.0%
Previous CABG 23 (3.1%)
Emergency/ urgent procedure 160 (21.8%
Interventional strategy
Ballooning 23 (3.1%)
Ballooning + Stent insertion 614 (83.5%
Ballooning + Stent insertion + Thrombus suction 98 (13.3%)
3-vessel disease 241 (32.8%
Hypotensive event 90 (12.2%)
IABP use 32 (4.4%)
Total volume of CM (mL) 237.0 ± 74.5
Volume of CM per weight (mL/kg) 3.69 ± 1.31
N-acetylcysteine 233 (33.5%
BUN (mg/dL) 18.0 ± 7.3
Creatinine (mg/dL) 1.08 ± 0.41
eGFR (mL/min/1.73m2) 74.5 ± 20.5
Hemoglobin (g/dL) 13.2 ± 1.8
Albumin (g/dL) 4.31 ± 0.48
hs-CRP (mg/L) 10.18 ± 28.8
Cholesterol (mg/dL) 164.5 ± 43.5
Triglyceride (mg/dL) 140.0 ± 82.3
Glucose (mg/dL) 124.6 ± 46.3
Ejection fraction (%) 57.5 ± 13.4
E/E' 13.3 ± 5.3
E/A 0.94 ± 0.48
Deceleration time (ms) 204.6 ± 50.1
LV mass (g) 213.6 ± 95.7
LV mass index (g/m2) 126.3 ± 88.6
LVDd (mm) 50.0 ± 5.0
LA volume index (mL/m2) 28.3 ± 9.7
Abbreviations: BMI body mass index; BP blood pressure; BUN blood urea nitrogen; C
contrast media; eGFR estimated glomerular filtration rate; hs-CRP high sensitivity C-r
LVDd left ventricular end-diastolic dimension.body mass index (BMI) than the non-CIN group. The
prevalence of hypertension, DM, emergency/ urgent
procedure, three-vessel coronary artery disease (3-VD),
previous coronary artery bypass graft surgery, and IABP
use during the PTCA was significantly higher in the CIN) CIN (n = 64) No CIN p
(n = 671)
70.8 ± 10.5 64.2 ± 10.5 <0.001
) 39 (60.9%) 475 (70.8%) 0.101
22.7 ± 3.3 24.7 ± 3.3 <0.001
119.5 ± 21.6 119.6 ± 14.4 0.979
69.0 ± 14.2 72.2 ± 9.3 0.119
) 52 (81.3%) 423 (63.0%) 0.004
) 39 (60.9%) 211 (31.4%) <0.001
5 (7.8%) 18 (2.7%) 0.042
) 23 (35.9%) 137 (20.4%) 0.004
0.521
1 (1.6%) 22 (3.3%)
) 52 (81.3%) 562 (83.8%)
11 (17.2%) 87 (13.0%)
) 39 (60.9%) 202 (30.1%) <0.001
25 (39.1%) 65 (9.7%) <0.001
16 (25.0%) 16 (2.4%) <0.001
222.8 ± 71.4 238.1 ± 74.7 0.179
4.09 ± 1.86 3.66 ± 1.25 0.179
) 15 (42.9%) 218 (33.0%) 0.230
24.2 ± 11.2 17.4 ± 6.6 <0.001
1.50 ± 0.75 1.04 ± 0.33 <0.001
54.5 ± 25.8 76.4 ± 18.9 <0.001
11.5 ± 2.1 13.3 ± 1.7 <0.001
3.85 ± 0.61 4.35 ± 0.44 <0.001
4 34.11 ± 47.95 7.84 ± 24.77 <0.001
167.5 ± 56.5 164.3 ± 42.2 0.722
126.0 ± 87.7 141.3 ± 81.7 0.035
156.2 ± 71.3 121.6 ± 42.1 <0.001
48.8 ± 12.8 58.6 ± 12.7 <0.001
18.2 ± 7.0 12.9 ± 4.9 <0.001
0.95 ± 0.37 0.94 ± 0.49 0.630
182.5 ± 50.5 206.7 ± 49.7 <0.001
233.1 ± 56.2 211.9 ± 98.4 0.001
144.0 ± 28.9 124.7 ± 91.9 <0.001
51.2 ± 5.6 49.9 ± 4.9 0.030
33.4 ± 11.6 27.8 ± 9.4 <0.001
ABG coronary artery bypass graft; CIN contrast-induced nephropathy; CM
eactive protein; IABP intra-aortic balloon pump; LA left atrium; LV left ventricle;
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laboratory findings, patients with CIN demonstrated
eGFR, hemoglobin, and albumin levels that were signifi-
cantly lower, while hs-CRP levels were significantly higherTable 2 Differences in variables according to tertiles of E/E’
Variables E/E’ ≤ 8
(n = 47)
Age (years) 57.0 ± 9.5
Sex (male) 42 (89.4%)
BMI (kg/m2) 23.7 ± 2.3
Systolic BP (mmHg) 115.3 ± 13.6
Diastolic BP (mmHg) 71.3 ± 9.4
Hypertension 21 (44.7%)
Diabetes mellitus 12 (25.5%)
Previous CABG 0 (0.0%)
Emergency/ urgent procedure 5 (10.6%)
Interventional strategy
Ballooning 1 (2.1%)
Ballooning + Stent insertion 42 (89.4%)
Ballooning + Stent insertion + Thrombus suction 4 (8.5%)
3-vessel disease 12 (25.5%)
Hypotensive event 3 (6.4%)
IABP use 0 (0.0%)
Total volume of CM (mL) 236.6 ± 89.4
Volume of CM per weight (mL/kg) 3.53 ± 1.19
N-acetylcysteine 24 (25.3%)
CIN 2 (4.3%)
BUN (mg/dL) 15.6 ± 3.5
Creatinine (mg/dL) 1.02 ± 0.25
eGFR (mL/min/1.73m2) 82.9 ± 17.9
Hemoglobin (g/dL) 13.9 ± 1.3
Albumin (g/dL) 4.45 ± 0.43
hs-CRP (mg/L) 6.85 ± 29.80
Cholesterol (mg/dL) 161.7 ± 42.7
Triglyceride (mg/dL) 143.9 ± 95.3
Glucose (mg/dL) 116.6 ± 41.3
Ejection fraction (%) 61.0 ± 10.0
E/E' 6.7 ± 0.8
E/A 0.98 ± 0.38
Deceleration time (ms) 207.5 ± 46.1
LV mass (g) 188.6 ± 41.6
LV mass index (g/m2) 107.2 ± 22.6
LVDd (mm) 48.4 ± 3.5
LA volume index (mL/m2) 22.3 ± 4.8
Abbreviations: BMI body mass index; BP blood pressure; BUN blood urea nitrogen; C
contrast media; eGFR estimated glomerular filtration rate; hs-CRP high sensitivity C-r
LVDd left ventricular end-diastolic dimension.compared to the non-CIN group. Echocardiographic find-
ings revealed that the EF and DT were decreased, while E/
E’ (18.2 ± 7.0 vs. 12.9 ± 4.9, p < 0.001), LVMI, LVDd, and
LAVI were significantly increased in patients with CIN.8 < E/E’ ≤ 15 E/E’ > 15 p
(n = 494) (n = 194)
63.4 ± 10.3 70.1 ± 9.6 0.036
375 (75.9%) 97 (50.0%) <0.001
24.7 ± 3.3 24.4 ± 3.6 0.061
119.9 ± 14.0 119.9 ± 17.9 0.018
72.6 ± 9.4 70.4 ± 10.8 0.150
305 (61.7%) 149 (76.8%) <0.001
154 (31.2%) 84 (43.3%) 0.005
13 (2.6%) 10 (5.2%) 0.130
103 (20.9%) 52 (26.8%) 0.038
0.680
14 (2.8%) 8 (4.1%)
415 (84.0%) 157 (80.9%)
65 (13.2%) 29 (14.9%)
134 (27.1%) 95 (49.0%) <0.001
45 (9.1%) 42 (21.6%) <0.001
11 (2.2%) 21 (10.8%) <0.001
237.9 ± 75.0 234.6 ± 69.1 0.956
3.62 ± 1.22 3.92 ± 1.53 0.176
144 (33.2%) 65 (39.2%) 0.071
20 (4.0%) 42 (21.6%) <0.001
17.3 ± 6.3 20.2 ± 9.6 0.112
1.04 ± 0.32 1.21 ± 0.57 0.848
77.4 ± 18.7 64.9 ± 22.4 0.071
13.4 ± 1.7 12.3 ± 1.9 0.058
4.39 ± 0.41 4.06 ± 0.54 0.308
7.67 ± 24.10 17.20 ± 36.50 <0.001
164.6 ± 42.9 165.4 ± 45.7 0.570
142.5 ± 85.1 132.4 ± 70.4 0.742
121.8 ± 41.6 133.7 ± 56.6 0.205
59.4 ± 12.1 52.7 ± 14.4 0.578
11.2 ± 2.1 20.4 ± 4.9 <0.001
0.90 ± 0.50 1.01 ± 0.44 0.065
207.9 ± 49.5 195.6 ± 52.0 0.699
212.1 ± 108.2 223.6 ± 64.5 0.014
121.5 ± 57.0 143.5 ± 145.8 0.003
49.8 ± 4.7 50.8 ± 5.8 0.014
26.6 ± 7.9 34.1 ± 11.9 <0.001
ABG coronary artery bypass graft; CIN contrast-induced nephropathy; CM
eactive protein; IABP intra-aortic balloon pump; LA left atrium; LV left ventricle;
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on the E/E’ values of 8 and 15, CIN occurred in 42 (21.6%)
patients in the highest tertile compared with 20 (4.0%) in
the middle and 2 (4.3%) in the lowest tertile (p < 0.001). In
addition, patients in the highest tertile were older and had
more hypertension, DM, and 3-VD. They also experienced
more hypotensive events and had IABPs placed more fre-
quently during procedure than patients in the middle and
lowest tertiles. Among the echocardiographic parameters,
LVMI, LVDd, and LAVI were significantly increased in the
highest tertile (Table 2).Risk factors for the development of CIN
Logistic regression analysis showed that higher E/E’ level
[odds ratio (OR) 1.147, 95% confidence interval (CI) 1.101-
1.194, p < 0.001 as a continuous variable/ OR 6.519, 95%
CI 3.774-11.260, p < 0.001 as a categorical variable] was a
significant risk factor for CIN (Table 3). After adjustment
for age, BMI, hypertension, DM, emergency/ urgent pro-
cedure, 3-VD, volume of CM per weight, use of IABP,
eGFR < 60 mL/min/1.73m2, hemoglobin, albumin, and hs-
CRP, E/E’ still remained as an independent risk factor (OR
1.091, 95% CI 1.026-1.159, p = 0.005 as a continuous vari-
able/ OR 3.435, 95% CI 1.522-7.755, p = 0.003 as a categor-
ical variable). In successive models, further adjustments
were made with other echocardiographic parameters, EFTable 3 Univariate logistic regression analysis for contrast-ind
Variables OR
Age > 75 years (vs. ≤ 75 years) 2.837
BMI (kg/m2) 0.808
Hypertension 2.541
Diabetes mellitus 3.401
Emergency/ urgent procedure 2.187
(vs. elective procedure)
3-vessel disease (vs. < 3-vessel involvement) 3.622
IABP use (vs. non-IABP use) 16.872
Volume of CM per weight (mL/kg) 1.250
eGFR < 60 mL/min/1.73m2 11.343
(vs. eGFR ≥ 60 mL/min/1.73m2)
Hemoglobin (g/dL) 0.571
Albumin (g/dL) 0.179
hs-CRP (mg/L) 1.017
E/E' 1.147
E/E' > 15 (vs. E/E’ ≤ 15) 6.519
EF ≤ 40% (vs. EF > 40%) 5.142
LAVI > 35 mL/m2 (vs. LAVI ≤ 35 mL/m2) 3.865
Data are presented as odds ratios (OR) and 95% confidence intervals (CI).
Abbreviations: BMI body mass index; IABP intra-aortic balloon pump; CM contrast m
C-reactive protein; EF ejection fraction; LAVI left atrial volume index.and LAVI. E/E’ > 15 was found to be a final determinant of
CIN (OR 2.579, 95% CI 1.082-5.964, p = 0.035) (Table 4).
Defining CIN as an increase in serum creatinine ≥ 0.3
mg/dL from the baseline value, according to the AKIN cri-
teria, did not change the independent role of E/E’ for the
prediction of CIN (OR 2.456, 95% CI 1.046-6.217, p =
0.044) (see Additional file 1).
In subgroup analysis, CIN occurred most often in
patients in the highest tertile of E/E’ irrespective of dia-
betes status (n = 15, 13.6% in non-DM group, p <
0.001/ n = 27, 32.1% in DM group, p < 0.001). A similar
finding was observed in patients with an eGFR < 60
mL/min/1.73m2 (n = 35, 47.3% in the highest tertile of
E/E’, p < 0.001), although there was no difference in the
development of CIN among the three tertiles of E/E’ in
patients with an eGFR ≥ 60 mL/min/1.73m2 (p = 0.199)
(Figure 1).Receiver operating characteristic analysis of E/E’ for the
development of CIN
To estimate the predictive accuracy of the echocardio-
graphic parameters for the development of CIN, ROC
analysis was performed. The area under the curve (AUC)
for E/E’, EF, and LAVI were 0.75 (95% CI 0.68-0.82, p <
0.001), 0.74 (95% CI 0.67-0.81, p < 0.001), and 0.66 (95%
CI 0.58-0.74, p < 0.001), respectively (Figure 2).uced nephropathy
95% CI p
1.038-1.097 <0.001
0.738-0.886 <0.001
1.330-4.852 0.005
2.006-55.766 <0.001
1.269-3.767 0.005
2.135-6.145 <0.001
7.670-37.113 <0.001
1.024-1.526 0.028
6.434-19.997 <0.001
0.490-0.664 <0.001
0.111-0.289 <0.001
1.010-1.023 <0.001
1.101-1.194 <0.001
3.774-11.260 <0.001
2.907-9.096 <0.001
2.230-6.700 <0.001
edia; eGFR estimated glomerular filtration rate; hs-CRP, high sensitivity
Table 4 Odds ratios and 95% confidence intervals for
contrast-induced nephropathy according to the E/E’
levels (Multivariate logistic regression analysis)
E/E’
OR 95% CI p
aModel 1 1.091 1.026-1.159 0.005
bModel 2 3.435 1.522-7.755 0.003
cModel 3 3.344 1.456-7.682 0.004
dModel 4 2.579 1.082-5.964 0.035
a Model 1 (odds ratio per 1 increase in E/E’) : adjusted for age (> 75 years vs. ≤
75 years), BMI, hypertension, diabetes, emergent/ urgent procedure, 3-vessel
disease, IABP use, volume of CM per weight, eGFR (< 60 mL/min/1.73m2 vs.
eGFR ≥ 60 mL/min/1.73m2), hemoglobin, albumin, and hs-CRP.
b Model 2 (odds ratio for E/E’ > 15 vs. E/E’ ≤ 15) : adjusted for age (> 75 years
vs. ≤ 75 years), BMI, hypertension, diabetes, emergent/ urgent procedure, 3-
vessel disease, IABP use, volume of CM per weight, eGFR (< 60 mL/min/1.73m2
vs. eGFR ≥ 60 mL/min/1.73m2), hemoglobin, albumin, and hs-CRP.
c Model 3 (odds ratio for E/E’ > 15 vs. E/E’ ≤ 15) : adjusted for Model 2 plus
ejection fraction (≤ 40% vs. > 40%).
d Model 4 (odds ratio for E/E’ > 15 vs. E/E’ ≤ 15) : adjusted for Model 3 plus
left atrial volume index (> 35 vs. ≤ 35).
Abbreviations: BMI body mass index; IABP intra-aortic balloon pump; CM
contrast media; eGFR estimated glomerular filtration rate; hs-CRP high
sensitivity C-reactive protein.
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E/E’ for CIN was 0.79 (95% CI 0.73-0.85, p < 0.001) (see
Additional file 2).
Survival analysis in CIN and diastolic dysfunction
During a mean follow-up of 17.9 months, 30 patients died.
The most common causes of death were cardiovascular dis-
ease (n = 16, 53.5%), followed by infection (n = 12, 40%).
Kaplan-Meier analysis showed higher mortality rates in
patients who developed CIN (n = 18, 28.1% vs. n = 11,
1.6%). In addition, there was a tendency toward higher
mortality in those with diastolic dysfunction and CIN (n =
14, 33.3%) (Figure 3). The two-year survival rates were
98.1% in patients without CIN or diastolic dysfunction,Figure 1 Relationship between diastolic dysfunction and the incidenc
dysfunction. CIN developed most frequently in patients in the highest ter
60 mL/min/1.73m2.95.8% in patients with diastolic dysfunction but no CIN,
72.6% in subjects with CIN and normal diastolic function,
and 58.1% in patients with both CIN and diastolic dys-
function (p < 0.001).
Comparison of E/E’ with previous risk scoring systems
for CIN
We reclassified our patients according to the risk strati-
fication systems suggested by Mehran et al. [14] and
Bartholomew et al. [4]. The incidence of CIN was well
proportional to both risk scores. Predictive perfor-
mances for CIN, estimated by AUC on ROC analysis,
were about 80% with previous methods and 75% with
E/E’ (see Additional file 3).
Discussion
This study showed that patients with CIN exhibited a
lower EF and higher E/E’ and LAVI on echocardiog-
raphy. In addition, the highest tertile of E/E’ was associ-
ated with a significantly increased risk of CIN, beyond
the well-known risk factors such as DM and renal fail-
ure. This implicates that diastolic dysfunction may be a
useful parameter for predicting the development of CIN.
There are both patient-related and patient-unrelated fac-
tors in the risk stratification systems for CIN. Patient-
related factors include chronic kidney disease (CKD), DM,
emergency/ urgent procedure, IABP use, CHF, age > 75
years, hypertension, anemia, a hypotensive episode, and
LVEF < 40%. Patient-unrelated factors include using ionic
and hyper-osmolar contrast agent, and high volume of
CM [9,14]. These factors play a role in the development of
CIN primarily by reducing effective renal blood flow,
consequently causing hypoxic change and the synthesis
of reactive oxygen species. Development of CIN has also
been attributed to increased sympathetic tone, renin-
angiotensin-aldosterone system (RAAS) activation, thee of CIN according to the presence of diabetes or renal
tile of E/E’ in all subgroups, except for patients with an eGFR ≥
Figure 2 Receiver operating characteristic curves for the development of CIN according to the echocardiographic variables (EF, E/E’,
and LAVI). The AUCs of EF, E/E, and LAVI were 0.74, 0.75, and 0.66, respectively (p < 0.001).
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pressin, catecholamines, endothelin, and pro-inflamma-
tory cytokines, and decreased nitric oxide (NO) levels.
These hemodynamic and neurohumoral alterations can
cause vascular endothelial cell damage and hypertrophic
change in the vascular smooth muscle cells, thus further
aggravating blood flow disturbances [5,18].Figure 3 Kaplan-Meier analysis for cumulative hazard of patient mort
diastolic dysfunction (E/E’ > 15) and/or CIN (p < 0.001).Although CHF is a well-proven risk factor for CIN,
only low ejection fraction has previously been studied,
among various components of heart failure such as dia-
stolic dysfunction, ventricular hypertrophy, and volume
overload [7,8,19]. This has likely been because a de-
creased effective circulatory volume is considered the
primary event in the development of CIN, in patientsality. There was a tendency toward higher mortality in patients with
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EF disappeared in the multivariate logistic regression ana-
lysis, whereas E/E’ remained a significant risk factor for
CIN (see Additional file 4). ROC analysis also showed a
considerable predictive accuracy for E/E’, which was com-
parable to that of EF (Figure 2). Moreover, most studies
demonstrated that EF only affects CIN rates in patients
with severe CHF of NYHA class 3–4 or an EF < 30-40%.
Given that CIN occurs in higher rates in CHF patients
with lower severity, this suggests that the hemodynamic
compromise status in milder stages of heart failure cannot
be properly represented by EF [8]. Actually, CIN occurred
in 18.2% of patients with EF < 40%, and 7.8% of patients
with EF ≥ 40% in our study. However, when patients with
severe CHF were excluded, E/E’ still was an independent
risk factor for CIN (OR 2.593, 95% CI 1.014-6.633, p =
0.041, data not shown). This finding suggests that diastolic
dysfunction may be a more reliable parameter to represent
the hemodynamic and neurohumoral alterations observed
in CHF.
Studies conducted in patients with CHF and preserved
LVEF showed a proportional increase in renal failure
according to the diastolic dysfunction [22]. The stiffer
the LV, the faster the eGFR declined [23]. The main
reasons for this include reduced LV functional reserve,
resting/ exercise-exacerbated systolic dysfunction, and
chronotropic incompetence, which are responsible for
the decrease in blood flow. These result in insufficient
tissue perfusion and an ischaemic injury to the kidney
[24-26]. Initially, LV hypertrophy occurs to compensate
for the stiffness of the LV, by increasing stroke volume.
But pathologic proliferation, fibrotic deposition, and cal-
cification of the ventricle become evident, and LV com-
pliance eventually decreases [27]. The same vicious cycle
in hemodynamics is thought to be the chief mechanism for
a higher E/E’ causing CIN. The adverse effect of diastolic
dysfunction on patient mortality is partly attributed to
these unfavorable geometric changes in the LV (Figure 3).
On the other hand, the neurohumoral changes occur-
ring during the development of CIN further aggravate
diastolic dysfunction. Angiotension II and aldosterone
promote the growth/ proliferation of both cardiomyocytes
and non-myocyte cells like fibroblasts [28]. Pro-inflamma-
tory cytokines such as TNF-α and IL-6 stimulate collagen
production by fibroblasts, and bring about a myocardio-
depressive effect [29]. We also demonstrated elevated
hs-CRP levels in patients in the highest tertile of E/E’
(Table 2). In addition, increased sympathetic tone
activates the β-catenin pathway in the cardiomyocytes
through the recruitment of Akt (protein kinase B).
This up-regulates the production of osteoblastogenic
proteins, further aggravating diastolic function [30].
Through these mutual effects on hemodynamic and
neurohumoral status, higher E/E’ is thought to causeacute kidney injury when patients with CHF are
exposed to the CM.
Furthermore, it should be noted that older age and in-
creased prevalences of hypertension, DM, and 3-VD
were present in subjects with diastolic dysfunction
(Table 2). These comorbidities are well-proven risk fac-
tors, and may potentiate the relationship between dia-
stolic dysfunction and CIN. In DM, advanced glycation
endproduct (AGE) mediates the crosslinking of collagen
fibres in the myocardium [31]. It also causes an inflam-
mation in the renal vascular system after binding to the
receptor of AGE (RAGE), through activation of NADPH
oxidase, MAP kinase, and the NF-κB pathway [32,33].
Because insulin and c-peptide are known to evoke the
overexpression of inducible endothelial NO synthase,
impaired pancreatic secretion is also expected to in-
crease E/E’ and exacerbate renal hemodynamics [34,35].
Actually, several studies demonstrated an improved ejec-
tion fraction/ diastolic function after correcting for these
metabolic abnormalities in diabetic CKD patients with a
kidney-pancreas co-transplantation [36,37]. Underlying
hypertension and CKD also strengthen the linkage
between diastolic dysfunction and CIN through the ef-
fects of uremic toxin [38,39], pressure overload, RAAS ac-
tivation, and markedly elevated expression of humoral
mediators such as catecholamines, endothelin, and para-
thyroid hormone [40].
There are several shortcomings to our study. Because
this was a retrospective study, limited data were avail-
able, which may have affected the conclusion by type II
error. Second, as estimating LVEDP during the PTCA
was not a routine practice in our institute, LVEDP and
their relationships with E/E’ and CIN could not be
presented. However, in other small cohort of 55 patients
who measured LVEDP during the PTCA in our hospital,
E/E’ levels were well correlated with LVEDP (r = 0.78,
p < 0.001). The ROC analysis demonstrated that the pre-
dictive accuracy of E/E’ for LVEDP > 15mmHg was 0.88
(p < 0.001, 95% CI 0.794-0.981). E/E’ > 15 had 81% sen-
sitivity and 86% specificity for LVEDP > 15 mmHg (see
Additional file 5). These results correspond closely with
previous studies by Sohn et al. and Ommen et al.
[11-13]. Moreover, E/E’ can be measured non-invasively
prior to PTCA, and warns the physicians to estimate
LVEDP during procedure and to monitor patients’ renal
function carefully after procedure, in advance, when
levels are elevated. Third, as only patients who were
suspected to have CAOD and had undergone an echo-
cardiography were included, selection bias may have
existed. Higher incidence rate of CIN in our study group
compared to that in previous studies conducted in the
general population supports this [1]. However, consider-
ing that interventional procedures using intravascular
CM are most closely related with the development of
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underlying cardiac disease and DM, the results of
present study can be applied to the high-risk patients
planning for the angioplasty. The uncontrolled use of
medications with vasomotor action or that modulate the
neurohumoral axis is another limitation. However,
former clinical trials using RAAS blockade, statins, cal-
cium channel blockers, beta-blockers, and diuretics
failed to derive a common consensus as to their effects
on CIN [41-43]. Lastly, as it was a single-center study,
further large-scale, randomized controlled multicenter
trials are needed to confirm and assess the clinical ap-
plicability of our findings.
Conclusions
In conclusion, we demonstrated that, among echocardio-
graphic parameters, E/E’ can be a useful predictor for the
development of CIN. To our knowledge, this is the first
study suggesting that assessment of diastolic dysfunction
should play a role in the risk stratification for CIN.
Additional file
Additional file 1: Univariate logistic regression analysis for
contrast-induced nephropathy, which was defined according to the
AKIN criteria.
Additional file 2: Receiver operating characteristic curves for CIN,
which was defined according to the AKIN criteria. The AUCs of EF,
E/E, and LAVI were 0.70, 0.79, and 0.69, respectively (p < 0.001).
Additional file 3: Predictive performances for CIN using various risk
scoring systems. The incidence of CIN was well proportional to both (a)
Mehran’s (renal failure was scored according to the eGFR: white bar, or
the Cr levels: black bar) and (b) Bartholomew’s risk scores. (c) E/E’ showed
a considerable predictive power for the development of CIN, which was
comparable to other risk stratification methods. The AUCs of E/E’ ,
Mehran’s score, and Bartholomew’s score were 0.75, 0.80, and 0.82,
respectively (p < 0.001).
Additional file 4: Multivariate logistic regression analysis for
contrast-induced nephropathy (detailed descriptions of Table 4).
Additional file 5: Correlation between E/E’ and LVEDP. (a) E/E’
showed a significant positive relationship with LVEDP on correlation
analysis. (b) Across increasing E/E’ tertiles, LVEDP levels were
incrementally higher. (c) ROC analysis revealed that the predictive
accuracy of E/E’ for LVEDP > 15 mmHg was 0.88 (p < 0.001, 95% CI
0.794-0.981).
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